Non-sterile Liquid Dose Formulation Development Service
Non-sterile liquid dosage forms represent a vital segment of the pharmaceutical market, particularly for patient populations where swallowing solid doses is impractical or impossible. CD BioGlyco offers a sophisticated non-sterile liquid dose formulation development service designed to address the intricate chemical and physical challenges inherent in liquid systems. Unlike solid forms, liquid doses are susceptible to rapid chemical degradation, microbial growth, and physical instability such as sedimentation or phase separation.
Our approach integrates advanced biopharmaceutical principles with robust engineering to develop high-performance oral solutions, suspensions, and emulsions. We focus on enhancing the solubility of BCS Class II and IV active pharmaceutical ingredients (APIs) while ensuring that the final product is palatable, stable, and easy to manufacture at scale. By leveraging our deep expertise in excipient-API interactions and microbiological quality, we help clients navigate the complexities of non-sterile manufacturing to deliver patient-centric products.
We employ a multidisciplinary technology stack to solve the most difficult liquid formulation hurdles:
Utilizing specialized lipid-based carriers to dramatically increase the solubility and intestinal absorption of hydrophobic APIs, ensuring consistent systemic exposure.
Advanced control of viscosity and thixotropic properties in suspensions to ensure excellent pourability while preventing the "caking" or permanent settling of particles.
Utilizing wet-milling and high-pressure homogenization to reduce API particle size to the nanometer range, improving dissolution rates and physical stability in complex liquid matrices.
Developing proprietary sweetener and aromatics combinations that effectively neutralize the bitterness of pharmaceutical actives without compromising chemical stability.
Utilizing automated microbiological challenge testing to determine the minimum effective concentration of antimicrobial agents, ensuring safety while minimizing excipient toxicity.
We provide a comprehensive suite of liquid formulation options tailored to the specific needs of modern clinical pipelines. We specialize in pediatric oral liquids, where taste, safety, and dosing accuracy are paramount. Our team is also highly experienced in developing High-Viscosity Topical Liquids and lotions that require precise dermal penetration profiles.
Our service scope includes:
We initiate the development process with a comprehensive analytical pre-formulation assessment. This involves exhaustive solubility mapping across various pH levels and solvents, detailed pH-stability profiling, and precise pKa determination. The generated data is critical for identifying the optimal "statility window" for the active pharmaceutical ingredient (API), guiding the rational selection between aqueous, cosolvent, or non-aqueous vehicle systems to ensure initial stability and solubility from the outset.
We employ high-throughput screening (HTS) platforms to systematically evaluate the compatibility of the API with a broad range of potential excipients, including buffers, antioxidants, chelating agents, and surfactants. This proactive screening identifies and mitigates risks of oxidative, hydrolytic, or other excipient-mediated degradation pathways, ensuring the formulation's chemical integrity throughout its shelf life.
In parallel with formulation activities, our analytical team develops, validates, and transfers specific stability-indicating methods (typically HPLC/UPLC). These methods are rigorously validated per ICH guidelines to accurately monitor API potency and quantitatively detect the emergence of any degradation impurities during accelerated and long-term stability studies, providing a critical quality control tool.
We design the formulation's microbiological quality attributes in accordance with global regulatory standards. This includes establishing appropriate microbial limits, selecting and optimizing effective preservative systems (for multidose products), and assessing the formulation's inherent growth promotion potential to ensure sterility or microbial control throughout the product's lifecycle.
We apply quality by design (QbD) principles to define and optimize critical process parameters (CPPs), such as mixing speed, time, temperature control, and filtration/sterilization parameters, for all unit operations. This structured approach ensures a well-understood and robust manufacturing process, enabling a seamless, de-risked transition from lab-scale to pilot-scale and ultimately to commercial-scale production.
Journal: Pharmaceutics
DOI: 10.3390/pharmaceutics14051032
IF: 5.5
Published: 2022
Results: In this comprehensive review, Hua et al. systematically examine the rectal route as a practical alternative for drug delivery when oral administration is infeasible due to clinical or pharmaceutical constraints. The article highlights the rectum's relatively stable environment, low enzymatic activity, and potential to bypass hepatic first-pass metabolism, making it suitable for both local and systemic drug actions. It delves into key physiological factors, such as anatomy, pH, and fluid volume, that influence absorption, while comparing rectal delivery to other gastrointestinal routes. The review covers conventional formulations like suppositories and enemas, alongside innovative systems including nanoparticles and mucoadhesive gels. Despite advancements, translational challenges persist, such as patient acceptability and formulation retention, underscoring the need for further research to harness the full potential of rectal drug delivery in personalized medicine.
Pediatric Therapeutics
Developing palatable, alcohol-free oral liquids that allow for flexible, weight-based dosing for children across various age groups.
Geriatric Medicine
Creating easy-to-swallow liquid alternatives for elderly patients with dysphagia, ensuring they can safely receive critical chronic medications.
Emergency Care
Engineering high-concentration oral drops that allow for rapid sublingual or oral administration in acute settings where intravenous access is not immediate.
Veterinary Pharmaceuticals
Designing flavored oral suspensions and solutions tailored to the specific taste preferences of companion animals, improving owner compliance.
Solubilization Mastery
We excel in turning hydrophobic APIs into stable liquid forms. We utilize advanced cosolvent systems and complexation techniques to increase aqueous solubility by orders of magnitude compared to standard methods.
Optimized Microbiological Safety
We adhere to the highest quality standards for non-sterile liquids. Our preservative systems maintain their efficacy even under extreme thermal stress, preventing the growth of objectionable organisms like Pseudomonas or Burkholderia.
Unrivaled Taste Masking
Our organoleptic specialists utilize "electronic tongue" technology to objectively measure and neutralize bitter notes, ensuring that our pediatric and geriatric formulations achieve industry-leading patient compliance scores.
Expert Rheological Profiling
We design "smart" suspensions that are thick enough to prevent sedimentation during storage but become fluid when shaken, ensuring every dose delivered is perfectly uniform.
CD BioGlyco solved a major oxidation issue with our lead liquid candidate. Their use of synergistic antioxidants extended our shelf life from 3 months to over 2 years.
— By Dr. S. K., Head of CMC
We were struggling with the scale-up of a high-viscosity emulsion. CD BioGlyco optimized the homogenization parameters, allowing us to produce consistent batches at the 500L scale without any phase separation.
— By Manager of Clinical Supply
The regulatory support from CD BioGlyco was exceptional. Their comprehensive stability and microbiology data made our filing process incredibly smooth and fast.
— By VP of R&D, Specialty Pharma
For clients working on advanced genetic or molecular therapies, we provide high-fidelity synthesis services that complement our liquid delivery expertise:
Specialized production of phosphorodiamidate morpholino oligos (PMO) for gene-silencing applications.
High-purity single guide RNA for precise CRISPR-Cas9 genome editing projects.
Innovative circRNA production for extended protein expression and improved stability.
Expert synthesis of peptide nucleic acids for robust diagnostic and therapeutic use.
CD BioGlyco is a leading partner in the development of non-sterile liquid dosage forms, bridging the gap between challenging APIs and ready products. Our focus on solubility, stability, and palatability ensures that your therapeutic is effective. To discuss your specific formulation challenges or to request a quote for our liquid dose development services, please contact us.
Reference
